Prices as of 2026/10/30 close
Company comparison · Mid-Tier Pharma & Drug Discovery
Nxera is the bigger company, with revenue of ¥29.6B — 1.6x Peptide Dream's ¥18.5B.
Peptide Dream earns more on each yen of sales, with an operating margin of -27.1% — 1.5 points above Nxera (-28.6%).
Revenue growth in the latest results: Nxera +2.7%, Peptide Dream −60.3%.
Nxera pays more on average — ¥12.6M against ¥11.7M at Peptide Dream.
Over the past year the shares moved Nxera +58.2%, Peptide Dream −28.4%.
Head-to-head wins11 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Peptide Dream aheadNxera 1 : Peptide Dream 2
Revenue: Nxera ¥29.6B / Peptide Dream ¥18.5B
ProfitabilityInvestors
Peptide Dream aheadNxera 1 : Peptide Dream 2
Operating margin: Nxera −28.6% / Peptide Dream −27.1%
GrowthInvestors
Nxera aheadNxera 1 : Peptide Dream 0
Revenue growth (YoY): Nxera +2.7% / Peptide Dream −60.3%
Stock & balance sheetInvestors
Nxera aheadNxera 2 : Peptide Dream 0
Share price, 1 year: Nxera +58.2% / Peptide Dream −28.4%
Pay & workforceJob seekers
EvenNxera 1 : Peptide Dream 1
Average salary: Nxera ¥12.6M / Peptide Dream ¥11.7M
| Metric | Nxera | Peptide Dream | Gap |
|---|---|---|---|
| Revenue | ◎¥29.6B | ¥18.5B | 1.6x |
| Operating profit | −¥8.5B | ◎−¥5.0B | |
| Net income | −¥12.5B | ◎−¥3.7B |
| Metric | Nxera | Peptide Dream | Gap |
|---|---|---|---|
| Operating margin | −28.6% | ◎−27.1% | 1.5pt |
| Net margin | −42.3% | ◎−20.2% | 22.1pt |
| ROE | −19.3% | — | |
| Revenue per employee | ◎¥592M | ¥118M | 5.0x |
| Metric | Nxera | Peptide Dream | Gap |
|---|---|---|---|
| Revenue growth (YoY) | ◎+2.7% | −60.3% | 63.0pt |
| Revenue CAGR | — | +18.6% | |
| Guidance: revenue growthnext FY plan | — | +72.8% |
| Metric | Nxera | Peptide Dream | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+58.2% | −28.4% | 86.7pt |
| Share price, 3 months | ◎+68.6% | +19.2% | 49.4pt |
| Equity ratio | 45.3% | — | |
| Share price (close) | ¥1,440 | ¥1,117 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Nxera | Peptide Dream | Gap |
|---|---|---|---|
| Average salary | ◎¥12.6M | ¥11.7M | ¥0.87M |
| Average tenure | 3.7 yrs | ◎5.3 yrs | 1.6 |
| Average age | 46.8 | 39.7 | 7.1 |
| Employees | 50 | 157 | 3.1x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥1,440+58.2% (1Y)
Nxera +58.2% over 1Y. Compared: Peptide Dream -28.4%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Nxera1 segments
Peptide Dream2 segments
AAverage annual salary from the securities filings: Nxera ¥12.6M, Peptide Dream ¥11.7M. Nxera pays the most. Averages also depend on staff age and job mix, so check the average age too (Nxera 46.8, Peptide Dream 39.7).
ARevenue in the latest results: Nxera ¥29.6B, Peptide Dream ¥18.5B. Nxera is the bigger company, with revenue of ¥29.6B — 1.6x Peptide Dream's ¥18.5B.
AOperating margins: Peptide Dream -27.1%, Nxera -28.6%. Peptide Dream turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Nxera +58.2%, Peptide Dream −28.4%. Nxera has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
